title: [Testicular germ cell tumors: prognosis].
abstract: OBJECTIVE
  To assess the prognosis of germ cell tumours of the testis based on a series of 60 patients.
  
  
  METHODS
  The files of 60 patients consecutively operated for germ cell tumour of the testis between February 1988 and January 2002 were reviewed. Tumours were classified as 35 seminomas (S) and 25 non-seminomatous germ cell tumours (NSGCT). In the S group, 32 patients received either prophylactic (28 pT1N0M0 tumours and 2 pT2N0M0 tumours) or therapeutic (1 pN2M0 tumour) adjuvant radiotherapy. The other 3 patients received BEP chemotherapy (1 pT3N0M0 tumour and 2 pN2M0 tumours). In the NSGCT group, 15 patients received adjuvant BEP chemotherapy (1 pT1N0M0 tumour, 5 pT2N0M0 tumours, and 7 pN2-3 and/or M+ tumours). Primary lymph node dissection was not performed in any patient, but 7 patients underwent lymph node dissection for residual masses after chemotherapy.
  
  
  RESULTS
  The mean follow-up after orchidectomy was 85.2 months. One patient in the S group developed left supraclavicular recurrence of a pT1N0M0 tumour, requiring 3 complementary cycles of BEP. All patients were in complete remission at the end of follow-up. In the NSGCT group, there was one recurrence after secondary lymph node dissection, requiring 3 complementary cycles of BEP. Only one death (4%) occurred after 18 months. All other patients were in complete remission at the end of follow-up.
  
  
  CONCLUSIONS
  The mortality rate of germ cell tumour of the testis was low in this series (0% for S and 4% for NSGCT at 7 years). These results are comparable to those reported in the literature. In our experience, stage pT1N0M0 NSGCT may be suitable for close surveillance, with no adjuvant therapy. It also does not appear justified to perform primary lymph node dissection in seminomas with lymph node involvement.
authors.affiliation: Service d'Urologie, Hôpital Cochin, 27, rue du Faubourg Saint-Jacques, 75014 Paris.
authors.forename: Makram
authors.initials: M
authors.lastname: Miladi
authors.forename: Michaël
authors.initials: M
authors.lastname: Peyromaure
authors.forename: Julien
authors.initials: J
authors.lastname: Remi
authors.forename: Philippe
authors.initials: P
authors.lastname: Beuzeboc
authors.forename: Bernard
authors.initials: B
authors.lastname: Debre
authors.forename: Marc
authors.initials: M
authors.lastname: Zerbib
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D018237:Germinoma / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D013736:Testicular Neoplasms / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents
vernacular_title: Tumeurs germinales du testicule: étude pronostique.